JOP20200069A1 - أجسام مضادة لـ pacap - Google Patents

أجسام مضادة لـ pacap

Info

Publication number
JOP20200069A1
JOP20200069A1 JOP/2020/0069A JOP20200069A JOP20200069A1 JO P20200069 A1 JOP20200069 A1 JO P20200069A1 JO P20200069 A JOP20200069 A JO P20200069A JO P20200069 A1 JOP20200069 A1 JO P20200069A1
Authority
JO
Jordan
Prior art keywords
antibodies
pacap antibody
migraine
compositions
treatment
Prior art date
Application number
JOP/2020/0069A
Other languages
English (en)
Inventor
Chetankumar Natvarlal Patel
Catherine Brautigam Beidler
Michael Parvin Johnson
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of JOP20200069A1 publication Critical patent/JOP20200069A1/ar

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/005—Enzyme inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1796—Receptors; Cell surface antigens; Cell surface determinants for hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pain & Pain Management (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Neurosurgery (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Cell Biology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

يتعلق الاختراع الحالي بأجسام مضادة لببتيد منشط سيكلاز الأدينيلات النخامية، وتركيبات تشتمل على تلك الأجسام المضادة، وطرق استخدام هذه الأجسام المضادة لعلاج الألم الذي يتضمن الصداع و/أو الصداع النصفي.
JOP/2020/0069A 2017-09-29 2018-09-20 أجسام مضادة لـ pacap JOP20200069A1 (ar)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762565278P 2017-09-29 2017-09-29
PCT/US2018/051898 WO2019067293A1 (en) 2017-09-29 2018-09-20 ANTI-PACAP ANTIBODIES

Publications (1)

Publication Number Publication Date
JOP20200069A1 true JOP20200069A1 (ar) 2020-04-28

Family

ID=63794713

Family Applications (1)

Application Number Title Priority Date Filing Date
JOP/2020/0069A JOP20200069A1 (ar) 2017-09-29 2018-09-20 أجسام مضادة لـ pacap

Country Status (25)

Country Link
US (3) US10519225B2 (ar)
EP (1) EP3688035A1 (ar)
JP (2) JP6952888B2 (ar)
KR (1) KR102453573B1 (ar)
CN (1) CN111164105B (ar)
AR (1) AR113022A1 (ar)
AU (1) AU2018341959B2 (ar)
BR (1) BR112020003628A2 (ar)
CA (1) CA3077304C (ar)
CL (1) CL2020000705A1 (ar)
CO (1) CO2020002170A2 (ar)
CR (1) CR20200127A (ar)
DO (1) DOP2020000060A (ar)
EA (1) EA202090563A1 (ar)
EC (1) ECSP20020293A (ar)
IL (1) IL273529A (ar)
JO (1) JOP20200069A1 (ar)
MA (1) MA50654A (ar)
MX (1) MX2020003563A (ar)
NZ (1) NZ762312A (ar)
PE (1) PE20201494A1 (ar)
SG (1) SG11202002572YA (ar)
TW (1) TWI701260B (ar)
WO (1) WO2019067293A1 (ar)
ZA (1) ZA202001058B (ar)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6752222B2 (ja) 2015-04-16 2020-09-09 アルダー・バイオファーマシューティカルズ・インコーポレーテッド 羞明を処置、予防、または阻害するための抗ｐａｃａｐ抗体及びそれらの抗原結合性断片の使用
WO2017181031A2 (en) * 2016-04-15 2017-10-19 Alder Biopharmaceuticals, Inc. Anti-pacap antibodies and uses thereof
WO2021076620A1 (en) 2019-10-15 2021-04-22 Eli Lilly And Company Recombinantly engineered, lipase/esterase-deficient mammalian cell lines
CN117916259A (zh) * 2021-09-30 2024-04-19 江苏恒瑞医药股份有限公司 特异性结合cgrp和pacap的抗原结合分子及其医药用途

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0522159B1 (en) 1990-03-17 2001-12-12 Takeda Chemical Industries, Ltd. Antibody to pituitary adenylate cyclase activating peptide-pacap, hybridoma and assay for pacap
US6037321A (en) 1995-05-03 2000-03-14 Biostar Inc. Fusion proteins comprising vasoactive intestinal peptide or PACAP
FR2826747B1 (fr) 2001-07-02 2005-02-25 Gemplus Card Int Procede et dispositif de traitement de donnees pour la personnalisation d'une application sur un dispositif communicant portatif, par exemple une carte a puce
EP1583550A2 (en) 2003-01-16 2005-10-12 D. Collen Research Foundation vzw Inhibition of pacap signalling for the prevention and treatment of thrombocytopenia
WO2012106407A2 (en) 2011-02-01 2012-08-09 The University Of Vermont And State Agricultural College Diagnostic and therapeutic methods and products related to anxiety disorders
JP6064861B2 (ja) 2013-03-05 2017-01-25 株式会社デンソー 熱電変換装置の製造方法
AU2014228924B2 (en) * 2013-03-15 2019-04-18 Amgen Inc. Human PAC1 antibodies
WO2015023890A1 (en) 2013-08-14 2015-02-19 The Arizona Board Of Regents On Behalf Of The University Of Arizona Glycosylated pacap/vip analogues with enhanced cns penetration for treatment of neurodegenerative diseases
JP6752222B2 (ja) 2015-04-16 2020-09-09 アルダー・バイオファーマシューティカルズ・インコーポレーテッド 羞明を処置、予防、または阻害するための抗ｐａｃａｐ抗体及びそれらの抗原結合性断片の使用
EP3390447A1 (en) * 2015-12-15 2018-10-24 Amgen Inc. Pacap antibodies and uses thereof
WO2017142961A1 (en) 2016-02-16 2017-08-24 The Arizona Board Of Regents On Behalf Of The University Of Arizona Treatment of traumatic brain injury or stroke

Also Published As

Publication number Publication date
ECSP20020293A (es) 2020-06-30
US20200131256A1 (en) 2020-04-30
KR20200040881A (ko) 2020-04-20
US10954292B2 (en) 2021-03-23
EA202090563A1 (ru) 2020-06-24
TW201920280A (zh) 2019-06-01
US10519225B2 (en) 2019-12-31
CN111164105B (zh) 2023-07-04
PE20201494A1 (es) 2020-12-29
MX2020003563A (es) 2020-08-03
AU2018341959A1 (en) 2020-03-05
CN111164105A (zh) 2020-05-15
CL2020000705A1 (es) 2020-09-11
SG11202002572YA (en) 2020-04-29
JP7221352B2 (ja) 2023-02-13
WO2019067293A1 (en) 2019-04-04
TWI701260B (zh) 2020-08-11
CA3077304C (en) 2023-08-01
JP2020535167A (ja) 2020-12-03
CA3077304A1 (en) 2019-04-04
IL273529A (en) 2020-05-31
CO2020002170A2 (es) 2020-04-01
DOP2020000060A (es) 2020-08-15
KR102453573B1 (ko) 2022-10-12
AU2018341959B2 (en) 2021-11-25
JP2022000049A (ja) 2022-01-04
NZ762312A (en) 2022-11-25
JP6952888B2 (ja) 2021-10-27
EP3688035A1 (en) 2020-08-05
ZA202001058B (en) 2022-06-29
US20210171616A1 (en) 2021-06-10
MA50654A (fr) 2020-08-05
US20190100579A1 (en) 2019-04-04
CR20200127A (es) 2020-04-08
AR113022A1 (es) 2020-01-15
BR112020003628A2 (pt) 2020-09-01

Similar Documents

Publication Publication Date Title
PH12020500671A1 (en) Antibodies specific for gucy2c and uses thereof
PH12018502538A1 (en) Antibodies to alpha-synuclein and uses thereof
NZ753515A (en) Methods for treatment of cancer comprising tigit-binding agents
MX2022004072A (es) Anticuerpos de factor xi y metodos de uso.
NZ738008A (en) Tigit-binding agents and uses thereof
NZ762312A (en) Anti-pacap antibody
EA202091130A1 (ru) Лиофилизованный препарат моноклонального антитела к транстиретину
WO2017151971A3 (en) METHODS RELATED TO ENGINEERED Fc CONSTRUCTS
MX2020014031A (es) Proteinas heterodimericas y usos de las mismas.
MX2022011972A (es) Composiciones que comprenden anticuerpos contra il6r para el tratamiento de la uveitis y el edema macular, y metodos de uso de las mismas.
MY186711A (en) Igf-1r antibody-drug-conjugate and its use for the treatment of cancer
MX2022002635A (es) Anticuerpos anti proteina similar a angiopoyetina 4 y metodos de uso.
TW201613977A (en) Angiopoetin-like 4 (ANGPTL4) antibodies and methods of use
MX2019009498A (es) Anticuerpos mimeticos de fgf21 y usos de los mismos.
MX2020005555A (es) Construcciones inmunogenicas de peptidos de tau.
MX2020006976A (es) Anticuerpos del receptor de tipo i del polipeptido activador de la adenilato?ciclasa hipofisaria (pac1) y sus usos.
MX2020011377A (es) Metodos y composiciones para el tratamiento de urticaria cronica.
ZA202205813B (en) Trpv1 epitopes and antibodies
WO2018129451A3 (en) Anti-fgfr antibodies and methods of use
MX2022000317A (es) Anticuerpos altamente potentes que se unen al receptor de muerte 4 y al receptor de muerte 5.